Pieris Pharms

PIRS NASDAQ
3.590
-0.220
-5.77%
After Hours: 3.590 0 0.00% 16:51 05/17 EDT
Open
3.770
Prev Close
3.810
High
3.780
Low
3.530
Volume
356.51K
Avg Vol (3M)
364.76K
52 Week High
6.55
52 Week Low
2.390
% Turnover
0.73%
Market Cap
176.53M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Pieris Pharms PIRS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
MORE >

Recently

Name
Price
%Change